- Home
- IMNM
IMNM
Immunome Inc.
as of 03-18-2026 3:56pm EST
$20.58
$0.13
-0.63%
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 2.8B | IPO Year: | 2020 |
| Target Price: | $32.80 | AVG Volume (30 days): | 906.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.43 | EPS Growth: | 51.40 |
| 52 Week Low/High: | $5.15 - $27.65 | Next Earning Date: | 03-03-2026 |
| Revenue: | $6,941,000 | Revenue Growth: | -23.23% |
| Revenue Growth (this year): | 18.41% | Revenue Growth (next year): | 863.23% |
| P/E Ratio: | -8.47 | Index: | N/A |
| Free Cash Flow: | -200604000.0 | FCF Growth: | N/A |
AI-Powered IMNM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.07%
74.07%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immunome Inc. (IMNM)
BIENAIME JEAN JACQUES
Buy
Director
IMNM Mar 11, 2026
Avg Cost/Share
$21.55
Shares
1,000
Total Value
$21,550.00
Owned After
38,415
SEC Form 4
BIENAIME JEAN JACQUES
Buy
Director
IMNM Mar 10, 2026
Avg Cost/Share
$22.12
Shares
1,000
Total Value
$22,120.00
Owned After
38,415
SEC Form 4
SIEGALL CLAY B
Buy
President and CEO
IMNM Dec 30, 2025
Avg Cost/Share
$21.15
Shares
4,729
Total Value
$100,018.35
Owned After
665,254
SEC Form 4
Barchas Isaac
Sell
Director
IMNM Dec 22, 2025
Avg Cost/Share
$22.03
Shares
383,200
Total Value
$8,330,079.62
Owned After
2,031,181
SIEGALL CLAY B
Buy
President and CEO
IMNM Dec 19, 2025
Avg Cost/Share
$20.48
Shares
7,278
Total Value
$149,053.44
Owned After
665,254
SEC Form 4
Tsai Philip
Buy
Chief Technical Officer
IMNM Dec 19, 2025
Avg Cost/Share
$20.49
Shares
10,000
Total Value
$204,900.00
Owned After
43,300
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | IMNM | Director | Mar 11, 2026 | Buy | $21.55 | 1,000 | $21,550.00 | 38,415 | |
| BIENAIME JEAN JACQUES | IMNM | Director | Mar 10, 2026 | Buy | $22.12 | 1,000 | $22,120.00 | 38,415 | |
| SIEGALL CLAY B | IMNM | President and CEO | Dec 30, 2025 | Buy | $21.15 | 4,729 | $100,018.35 | 665,254 | |
| Barchas Isaac | IMNM | Director | Dec 22, 2025 | Sell | $22.03 | 383,200 | $8,330,079.62 | 2,031,181 | |
| SIEGALL CLAY B | IMNM | President and CEO | Dec 19, 2025 | Buy | $20.48 | 7,278 | $149,053.44 | 665,254 | |
| Tsai Philip | IMNM | Chief Technical Officer | Dec 19, 2025 | Buy | $20.49 | 10,000 | $204,900.00 | 43,300 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 3, 2026 · 54% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 3, 2026 · 54% conf.
AI Prediction SELL
1D
-1.59%
$21.30
Act: +4.06%
5D
-9.24%
$19.64
Act: -3.66%
20D
-5.28%
$20.50
Price: $21.64 Prob +5D: 23% AUC: 1.000
0001193125-26-088141
8-K
0001472012false00014720122026-03-032026-03-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2026
Immunome, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-39580
77-0694340
(state or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
18702 N. Creek Parkway, Suite 100 Bothell, WA
98011
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (425) 939-7410
N/A (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
IMNM
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 3, 2026, Immunome, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing. Item 9.01 Financial Statements and Exhibits. (d)
Exhibit Number
Description
99.1
Press Release dated March 3, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 3, 2026
Immunome, Inc.
By:
/s/ Max Rosett
Name:
Max Rosett
Title:
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001193125-25-269538
8-K
false000147201200014720122025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
Immunome, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-39580
77-0694340
(state or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
18702 N. Creek Parkway, Suite 100 Bothell, WA
98011
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (425) 939-7410
N/A (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
IMNM
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Immunome, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2025 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing. Item 9.01 Financial Statements and Exhibits. (d)
Exhibit Number
Description
99.1
Press Release dated November 6, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025
Immunome, Inc.
By:
/s/ Max Rosett
Name:
Max Rosett
Title:
Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0000950170-25-104015
8-K
0001472012false00014720122025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2025
Immunome, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-39580
77-0694340
(state or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
18702 N. Creek Parkway, Suite 100 Bothell, WA
98011
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (425) 939-7410
N/A (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
IMNM
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 6, 2025, Immunome, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2025 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing. Item 9.01 Financial Statements and Exhibits. (d)
Exhibit Number
Description
99.1
Press Release dated August 6, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2025
Immunome, Inc.
By:
/s/ Max Rosett
Name:
Max Rosett
Title:
Chief Financial Officer
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Compare IMNM vs Leading Stocks
See how IMNM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.